These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22012848)

  • 1. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
    Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
    J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.
    Darreh-Shori T; Modiri N; Blennow K; Baza S; Kamil C; Ahmed H; Andreasen N; Nordberg A
    Neurobiol Aging; 2011 Jul; 32(7):1236-48. PubMed ID: 19713000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
    Darreh-Shori T; Forsberg A; Modiri N; Andreasen N; Blennow K; Kamil C; Ahmed H; Almkvist O; Långström B; Nordberg A
    Neurobiol Aging; 2011 Dec; 32(12):2320.e15-32. PubMed ID: 20538374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases.
    Maetzler W; Keller S; Michelis J; Koehler N; Stransky E; Becker C; Schulte C; Melms A; Gasser T; Berg D
    Neurobiol Dis; 2009 Aug; 35(2):296-301. PubMed ID: 19481150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
    Darreh-Shori T; Brimijoin S; Kadir A; Almkvist O; Nordberg A
    Neurobiol Dis; 2006 Nov; 24(2):326-33. PubMed ID: 16973370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
    Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
    Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
    Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
    Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease.
    Darreh-Shori T; Vijayaraghavan S; Aeinehband S; Piehl F; Lindblom RP; Nilsson B; Ekdahl KN; Långström B; Almkvist O; Nordberg A
    Neurobiol Aging; 2013 Nov; 34(11):2465-81. PubMed ID: 23759148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.
    Vijayaraghavan S; Darreh-Shori T; Rongve A; Berge G; Sando SB; White LR; Auestad BH; Witoelar A; Andreassen OA; Ulstein ID; Aarsland D
    J Alzheimers Dis; 2016; 50(2):567-76. PubMed ID: 26757188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.
    Raygani AV; Zahrai M; Soltanzadeh A; Doosti M; Javadi E; Pourmotabbed T
    Neurosci Lett; 2004 Nov; 371(2-3):142-6. PubMed ID: 15519745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers.
    Lane RM; Darreh-Shori T; Junge C; Li D; Yang Q; Edwards AL; Graham DL; Moore K; Mummery CJ
    BMC Neurol; 2024 Apr; 24(1):116. PubMed ID: 38594621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
    Combarros O; Riancho JA; Infante J; Sañudo C; Llorca J; Zarrabeitia MT; Berciano J
    Dement Geriatr Cogn Disord; 2005; 20(2-3):153-7. PubMed ID: 16020944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
    Patterson CE; Todd SA; Passmore AP
    Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease.
    Pievani M; Galluzzi S; Thompson PM; Rasser PE; Bonetti M; Frisoni GB
    Neuroimage; 2011 Apr; 55(3):909-19. PubMed ID: 21224004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.
    Varges D; Jung K; Gawinecka J; Heinemann U; Schmitz M; von Ahsen N; Krasnianski A; Armstrong VW; Zerr I
    J Alzheimers Dis; 2011; 23(4):717-26. PubMed ID: 21157024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
    Sokolow S; Li X; Chen L; Taylor KD; Rotter JI; Rissman RA; Aisen PS; Apostolova LG
    J Alzheimers Dis; 2017; 56(1):229-237. PubMed ID: 27911294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.